HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

Modern Pathology

Volumn 24, Issue 7, 2011, Pages 899-907

  Hu, Yingchuan ^a   Bandla, Santhoshi ^a   Godfrey, Tony E ^a   Tan, Dongfeng ^c   Luketich, James D ^d   Pennathur, Arjun ^d   Qiu, Xing ^b   Hicks, David G ^a   Peters, Jeffrey H ^a   Zhou, Zhongren ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

amplification; chromogenic in situ hybridization; DNA microarray; esophageal adenocarcinoma; HER2; immunohistochemistry; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 79959981720     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.47     Document Type: Article

References (32)

1. Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J pathol 1998;152:135-144. (Pubitemid 28028054)
2. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009;174: 1940-1948.
3. Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North Am 2005;85: 621-630. (Pubitemid 40779380)
4. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Annals of surgery 2003;238:486- 494;discussion 94-5.
5. Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001;72:1918-1924 discussion 24-5.
6. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146. (Pubitemid 40277094)
7. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
8. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
9. Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-318. (Pubitemid 29157789)
10. Rossi E, Villanacci V, Bassotti G, et al. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol 2006;15: 125-130. (Pubitemid 44325472)
11. Rossi E, Grisanti S, Villanacci V, et al. Her-2 overexpression/ amplification in Barrett's esophagus predicts early transition from dysplasia to adenocarcinoma: A Clinico-Pathologic Study. J Cell Mol Med 2009;13:3826-3833.
12. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-129. (Pubitemid 44967957)
13. Langer R, Von Rahden BH, Nahrig J, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006;59: 631-634. (Pubitemid 43886048)
14. Dreilich M, Wanders A, Brattstrom D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224-231. (Pubitemid 44027082)
15. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
16. Zhang D, Salto-Tellez M, Do E, et al. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34:362-368. (Pubitemid 36535020)
17. Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-39. (Pubitemid 30054384)
18. Sato S, Kajiyama Y, Sugano M, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005;61:203-211. (Pubitemid 40039124)
19. Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-409. (Pubitemid 46108313)
20. Jorgensen JT. Target HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
21. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
23. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
24. Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007;13:5115-5123. (Pubitemid 47502079)
25. Albrecht B, Hausmann M, Zitzelsberger H, et al. Arraybased comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 2004;203:780-788. (Pubitemid 38961564)
26. van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-752. (Pubitemid 29076077)
27. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett's with highgrade dysplasia. Clin Cancer Res 2003;9:4819-4825. (Pubitemid 37323285)
28. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
29. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820. (Pubitemid 43290919)
30. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
31. Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 2009;55:716-723.
32. Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol 2009;131: 490-497.